These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 2296272)

  • 1. Pancreatic function in infants identified as having cystic fibrosis in a neonatal screening program.
    Waters DL; Dorney SF; Gaskin KJ; Gruca MA; O'Halloran M; Wilcken B
    N Engl J Med; 1990 Feb; 322(5):303-8. PubMed ID: 2296272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group.
    Farrell PM; Kosorok MR; Laxova A; Shen G; Koscik RE; Bruns WT; Splaingard M; Mischler EH
    N Engl J Med; 1997 Oct; 337(14):963-9. PubMed ID: 9395429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum immunoreactive pancreatic lipase and cationic trypsinogen for the assessment of exocrine pancreatic function in older patients with cystic fibrosis.
    Cleghorn G; Benjamin L; Corey M; Forstner G; Dati F; Durie P
    Pediatrics; 1986 Mar; 77(3):301-6. PubMed ID: 3951910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of tests of exocrine and endocrine pancreatic function in older patients with cystic fibrosis.
    Lamers CB; Jansen JB; Hafkenscheid JC; Jongerius CM
    Pancreas; 1990; 5(1):65-9. PubMed ID: 1688391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of pancreatic function in screened infants with cystic fibrosis.
    Gaskin K; Waters D; Dorney S; Gruca M; O'Halloran M; Wilcken B
    Pediatr Pulmonol Suppl; 1991; 7():69-71. PubMed ID: 1782134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations.
    Hammond KB; Abman SH; Sokol RJ; Accurso FJ
    N Engl J Med; 1991 Sep; 325(11):769-74. PubMed ID: 1870650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the diagnostic value of serum pancreatic isoamylase and immunoreactive trypsin measurement in patients with cystic fibrosis.
    Brown RC; Chalmers DM; Rowe VL; Kelleher J; Littlewood JM; Losowsky MS
    J Clin Pathol; 1982 May; 35(5):547-9. PubMed ID: 7085899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening.
    Sontag MK; Corey M; Hokanson JE; Marshall JA; Sommer SS; Zerbe GO; Accurso FJ
    J Pediatr; 2006 Nov; 149(5):650-657. PubMed ID: 17095337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoreactive trypsin/DNA newborn screening for cystic fibrosis: should the R117H variant be included in CFTR mutation panels?
    Scotet V; Audrézet MP; Roussey M; Rault G; Dirou-Prigent A; Journel H; Moisan-Petit V; Storni V; Férec C
    Pediatrics; 2006 Nov; 118(5):e1523-9. PubMed ID: 17015492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CF-CIRC study: a French collaborative study to assess the accuracy of cystic fibrosis diagnosis in neonatal screening.
    Sermet-Gaudelus I; Roussel D; Bui S; Deneuville E; Huet F; Reix P; Bellon G; Lenoir G; Edelman A
    BMC Pediatr; 2006 Oct; 6():25. PubMed ID: 17018149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystic fibrosis diagnosed after 2 months of age leads to worse outcomes and requires more therapy.
    Sims EJ; Clark A; McCormick J; Mehta G; Connett G; Mehta A;
    Pediatrics; 2007 Jan; 119(1):19-28. PubMed ID: 17200267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does cystic fibrosis neonatal screening detect atypical CF forms? Extended genetic characterization and 4-year clinical follow-up.
    Narzi L; Ferraguti G; Stamato A; Narzi F; Valentini SB; Lelli A; Delaroche I; Lucarelli M; Strom R; Quattrucci S
    Clin Genet; 2007 Jul; 72(1):39-46. PubMed ID: 17594398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and cystic fibrosis genotype.
    Augarten A; Ben Tov A; Madgar I; Barak A; Akons H; Laufer J; Efrati O; Aviram M; Bentur L; Blau H; Paret G; Wilschanski M; Kerem BS; Yahav Y
    Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):164-8. PubMed ID: 18301294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508).
    Kerem E; Corey M; Kerem BS; Rommens J; Markiewicz D; Levison H; Tsui LC; Durie P
    N Engl J Med; 1990 Nov; 323(22):1517-22. PubMed ID: 2233932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of individuals with cystic fibrosis in New Zealand.
    Wesley A; Dawson K; Hewitt C; Kerr A
    N Z Med J; 1993 Feb; 106(949):28-30. PubMed ID: 8464584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neonatal screening for cystic fibrosis does not affect time to first infection with Pseudomonas aeruginosa.
    Baussano I; Tardivo I; Bellezza-Fontana R; Forneris MP; Lezo A; Anfossi L; Castello M; Aleksandar V; Bignamini E
    Pediatrics; 2006 Sep; 118(3):888-95. PubMed ID: 16950978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis and neonatal screening of cystic fibrosis].
    Roussey M; Deneuville E; Dabadie A
    Rev Prat; 2003 Jan; 53(2):135-40. PubMed ID: 12664843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of 4 neonatal screening strategies for cystic fibrosis.
    van den Akker-van Marle ME; Dankert HM; Verkerk PH; Dankert-Roelse JE
    Pediatrics; 2006 Sep; 118(3):896-905. PubMed ID: 16950979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faecal elastase-1 and fat-soluble vitamin profiles in patients with cystic fibrosis in Western Norway.
    Dorlöchter L; Aksnes L; Fluge G
    Eur J Nutr; 2002 Aug; 41(4):148-52. PubMed ID: 12242582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic function and extended mutation analysis in DeltaF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels.
    Massie RJ; Wilcken B; Van Asperen P; Dorney S; Gruca M; Wiley V; Gaskin K
    J Pediatr; 2000 Aug; 137(2):214-20. PubMed ID: 10931414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.